Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer.
Despite widespread interest, few serum biomarkers have been introduced to the clinic over the past 20 years. Each approach to ovarian cancer biomarker discovery has its own advantages and disadvantages and it seems likely that a global biomarker discovery platform that mines all possible sources for biomarkers might be more useful. Such data could be combined with information from relevant microarray data, bioinformatic analyses and literature searches. This proposed integrated systems biology approach has the potential to yield promising ovarian cancer markers for diagnosis, prognosis and monitoring of patients during therapy.
Kulasingam
Vathany
V
Vathany Kulasingam, Maria P. Pavlou and Eleftherios P. Diamandis are at the Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5G 1X5, Ontario, Canada.
Pavlou
Maria P
MP
Diamandis
Eleftherios P
EP
D014408:Biomarkers, Tumor / Q000032:analysis*; D055088:Early Detection of Cancer / Q000379:methods*; D005260:Female; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D010051:Ovarian Neoplasms / Q000175:diagnosis*
D014408:Biomarkers, Tumor
Mol Cell Proteomics. 2002 Nov;1(11):845-67
12488461
Clin Chem. 2009 Jul;55(7):1427-30
19443560
Nat Clin Pract Oncol. 2008 Oct;5(10):577-87
18648354
Oncology. 1989;46(5):318-22
2779946
Clin Chem. 2006 Apr;52(4):771-2; author reply 772
16595832
Lancet. 2002 Feb 16;359(9306):572-7
11867112
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66
17255266
Gynecol Oncol. 2006 Nov;103(2):405-16
16725184
Gynecol Oncol. 2003 Jan;88(1 Pt 2):S136-9
12586105
Biomark Insights. 2007 Oct 16;2:369-75
19662218
Cancer Res. 2004 Aug 15;64(16):5882-90
15313933
J Mol Med (Berl). 2003 Oct;81(10):600-12
12928786
Clin Biochem. 2010 Mar;43(4-5):355-61
19883638
Lancet Oncol. 2009 Apr;10(4):327-40
19282241
Int J Cancer. 2008 Nov 1;123(9):2007-12
18712711
J Natl Cancer Inst. 2004 Mar 3;96(5):353-6
14996856
Mol Cell Proteomics. 2004 Apr;3(4):367-78
14990683
Br J Cancer. 2009 Apr 21;100(8):1315-9
19337252
Clin Chem. 2005 Aug;51(8):1525-8
15951319
Cancer Res. 2003 Jul 1;63(13):3695-700
12839961
J Proteome Res. 2008 Aug;7(8):3613-8
18624399
Pharmacogenomics. 2005 Sep;6(6):647-53
16143004
J Proteome Res. 2009 Oct;8(10):4705-13
19663500
Nat Rev Cancer. 2007 Sep;7(9):659-72
17721431
Lab Invest. 2007 Aug;87(8):737-54
17558419
J Proteome Res. 2008 Jan;7(1):339-51
18076136
Mol Cell Proteomics. 2004 Apr;3(4):355-66
14764655
Clin Cancer Res. 2003 Jan;9(1):44-51
12538450
Ann Oncol. 2001 Oct;12(10):1353-7
11762804
Nat Biotechnol. 2009 Jul;27(7):633-41
19561596
J Natl Cancer Inst. 2002 Nov 20;94(22):1697-703
12441325
Gynecol Oncol. 2008 Feb;108(2):402-8
18061248
PLoS One. 2009 Nov 19;4(11):e7916
19936259
J Proteome Res. 2007 Dec;6(12):4549-55
17970587
Nat Rev Cancer. 2007 Sep;7(9):645-58
17687385
J Am Coll Surg. 2004 Jun;198(6):999-1011
15194082
Mol Cell Proteomics. 2009 Apr;8(4):661-9
19047685
PLoS One. 2008 Jun 18;3(6):e2425
18560578
Ann Oncol. 1996 Apr;7(4):361-4
8805927
Proteomics. 2002 Jan;2(1):76-84
11788994
Clin Chem. 2005 Sep;51(9):1637-49
16002455
Cancer. 2004 May 15;100(10):2139-47
15139056
Am J Obstet Gynecol. 2008 Sep;199(3):215-23
18468571
Clin Cancer Res. 2008 Feb 15;14(4):1065-72
18258665
J Natl Cancer Inst. 2008 Oct 15;100(20):1432-8
18840817
Nat Biotechnol. 2006 Aug;24(8):971-83
16900146
J Natl Cancer Inst. 2005 Feb 16;97(4):315-9
15713968
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
J Proteome Res. 2007 Apr;6(4):1440-50
17315909
N Engl J Med. 2004 Dec 9;351(24):2519-29
15590954
J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61
11459866
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3410-5
12624183
Nature. 2007 Jun 21;447(7147):966-71
17515920
J Clin Oncol. 2004 Dec 1;22(23):4700-10
15505275
Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:203-9
14763176
Gynecol Oncol. 2009 Jan;112(1):40-6
18851871
BMB Rep. 2008 Sep 30;41(9):626-34
18823585
Curr Opin Chem Biol. 2008 Feb;12(1):72-7
18295612